However, clear cell carcinoma has shown a more durable response than other epithelial ovarian cancers to checkpoint therapies, likely due to related differences in tumor biology such as higher rates of microsatellite instability, tumor infiltrating lymphocytes, and PDL1 expression [7, 16, 17]. The gene discussed is CD274; the disease is ovarian carcinoma.